Cbay stock forecast.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary ...Dec 1, 2023 · The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low. 3 Wall Street analysts have issued twelve-month target prices for Aldeyra Therapeutics' shares. Their ALDX share price targets range from $8.00 to $15.00. On average, they expect the company's share price to reach $12.33 in the next year. This suggests a possible upside of 370.7% from the stock's current price.The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low.

See the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Forecast . Price target. 24.08 0.00 0.00%. The 12 analysts offering 1 year price forecasts for CBAY have a max estimate of — and a min estimate of —. Analyst rating. Based on 13 analysts giving stock ratings to CBAY in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreDiscover historical prices for CBAY stock on Yahoo Finance. View daily, weekly or monthly format back to when CymaBay Therapeutics, Inc. stock was issued.

16 Wall Street analysts have issued 12 month price targets for Exelixis' stock. Their EXEL share price targets range from $18.00 to $32.00. On average, they anticipate the company's stock price to reach $25.44 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View analysts price …According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecasts

Dec 1, 2023 · CBAY Earnings Date and Information. CymaBay Therapeutics last posted its earnings results on November 7th, 2023. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.02. The average Guardforce Ai Co stock price prediction forecasts a potential upside of 260.82% from the current GFAI share price of $3.88. What is GFAI's forecast return on assets (ROA) for 2023-2026? (NASDAQ: GFAI) forecast ROA is N/A, which is lower than the forecast US Security & Protection Services industry average of N/A.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for AYRO Inc have a median target of 9.00, with a high estimate of 9.00 and a low estimate of 9.00. The median estimate ...CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline ...Sep 8, 2023 · He kept his outperform rating on CBAY stock and raised his price target to 20 from 18. Notably, CymaBay stock has a best-possible Relative Strength Rating of 99, according to IBD Digital. This ...

CymaBay Therapeutics Inc (CBAY) stock is trading at $11.76 as of 11:26 AM on Monday, Jul 3, a rise of $0.81, or 7.39% from the previous closing price of $10.95. The stock has traded between $10.95 and $11.77 so far today. Volume today is low. So far 1,522,720 shares have traded compared to average volume of 2,310,531 shares.

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.

Crescent Point Energy Corp. (TSE:CPG) issued its quarterly earnings results on Thursday, November, 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by $0.09. The business earned $1.25 billion during the quarter, compared to analyst estimates of $1.20 billion.Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $24.40 with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 29.93% change from the last price of $18.78. Highest Price Target $33.00. Average Price Target $24.40. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Coterra Energy share forecasts, stock quote and buy / sell signals below. According to present data Coterra Energy's CTRA shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ...CymaBay Therapeutics Inc (CBAY) stock is trading at $11.76 as of 11:26 AM on Monday, Jul 3, a rise of $0.81, or 7.39% from the previous closing price of $10.95. The stock has traded between $10.95 and $11.77 so far today. Volume today is low. So far 1,522,720 shares have traded compared to average volume of 2,310,531 shares.CBAY 8.19%. 70. See CBAY Report. CymaBay Therapeutics Inc ( CBAY) is near the top in its industry group according to InvestorsObserver. CBAY gets an overall rating of 80. That means it scores higher than 80 percent of stocks. CymaBay Therapeutics Inc gets a 91 rank in the Biotechnology industry. Biotechnology is number 13 out of 148 …

For CymaBay Therapeutics stock forecast for 2023, 1 predictions are offered for each month of 2023 with average CymaBay Therapeutics stock forecast of $19.97, a high forecast of $19.97, and a low forecast of $19.97. The average CymaBay Therapeutics stock forecast 2023 represents a 4.58% increase from the last price of $19.1000003814697.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Cymabay Therapeutics Inc Stock Price Forecast, "CBAY" Predictons for2023. Markets; Forecast . Crypto Forecasts; Top 5 Crypto forecasts; Tether Usdt forecast; Bitcoin forecast; Ethereum forecast; Xrp forecast; First Digital Usd forecast; Stock Forecasts (US) ... Cryptocurrency News, Crypto, Stock, Forex Predictions, Forecasts & Charts – …What are analysts’ forecasts for CBAY stock? Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CBAY stock returns are also predicted based on historical data. According to our research, CBAY stock is a bad long-term investment.CymaBay (CBAY) Stock Up on Positive Results From PBC Study. ... The median home sale price will fall 1.7% next year after eking out an anticipated 0.2% gain in 2023, according to the forecast.

A high-level overview of eBay Inc. (EBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Dec 1, 2023 · CBAY Earnings Date and Information. CymaBay Therapeutics last posted its earnings results on November 7th, 2023. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.02.

The CymaBay Therapeutics stock forecast for tomorrow is $ 19.01, which would represent a -0.48% loss compared to the current price. In the next week, the price of CBAY is expected to decrease by -5.95% and hit $ 17.96. As far as the long-term CymaBay Therapeutics stock forecast is concerned ... CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates. by Zacks Equity Research Published on November 10,2021. CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue ...Analyst Forecast. According to 12 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is $22.64, which is an increase of 18.35% from the latest price.The CymaBay Therapeutics stock forecast for tomorrow is $ 19.01, which would represent a -0.48% loss compared to the current price. In the next week, the price of CBAY is expected to decrease by -5.95% and hit $ 17.96. As far as the long-term CymaBay Therapeutics stock forecast is concerned ... Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather.EXEL Stock 12 Months Forecast. Based on 13 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $25.75 with a high forecast of $32.00 and a low forecast of $18.00. The average price target represents a 25.06% change from the last price of $20.59.You Should Look At The Stock Forecast For Cymabay Therapeutics Inc (NASDAQ: CBAY). Carlyle Group Inc (NASDAQ: CG): One Stock To Trade As Economic Progress Advances Why Invesco Ltd (NYSE: IVZ) Is A Stock Not To Be Discarded In 2023 Astrazeneca plc ADR (NASDAQ: AZN): A Stock Worth Thinking About Today Procter & …Cymabay Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction. ... CBAY Related stocks. Symbol 3M %Chg ; CBAY +35.42% : Cymabay Therapeutics: RDY ...

Yasmeen Rahimi's average stock forecast success ratio is 24.4% with an ... CBAY CymaBay Therapeutics ENTA Enanta Pharmaceuticals ETN Eatonplc ICPT Intercept ...

VKTX Signals & Forecast. The Viking Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some …

Stock Price Forecast The 1 analysts offering 12-month price forecasts for Creative Medical Technology Holdings Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate ... The average Guardforce Ai Co stock price prediction forecasts a potential upside of 260.82% from the current GFAI share price of $3.88. What is GFAI's forecast return on assets (ROA) for 2023-2026? (NASDAQ: GFAI) forecast ROA is N/A, which is lower than the forecast US Security & Protection Services industry average of N/A.The stock is selling for $9.87 and its $13.89 average price target suggests a 12-month upside potential of ~41%. (See CBAY stock forecast ) Cerevel Therapeutics ( CERE )Find real-time VSTM - Verastem Inc stock quotes, company profile, news and forecasts from CNN Business.Over the past 3 months, 14 analysts have published their opinion on CymaBay Therapeutics (NASDAQ:CBAY) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Find the latest AFC Gamma, Inc. (AFCG) stock quote, history, news and other vital information to help you with your stock trading and investing.The stock is selling for $9.87 and its $13.89 average price target suggests a 12-month upside potential of ~41%. (See CBAY stock forecast ) Cerevel Therapeutics ( CERE )(See CBAY stock forecast)Cerevel Therapeutics (CERE)The next Edelman choice is Cerevel, a company established in 2018 that specializes in the field of neuroscience. Cerevel's focus is on the ...PTC Therapeutics Inc. -3.71%. $1.57B. CBAY | Complete CymaBay Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...

Based on short-term price targets offered by 11 analysts, the average price target for CymaBay Therapeutics Inc. comes to $24.45. The forecasts range from a low of $20.00 to a high of $34.00.Nov 21, 2023 · According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecasts Cymabay Therapeutics Stock Chart and Share Price Forecast, Short-Term "CBAY" Stock Prediction for Next Days and Weeks Walletinvestor.com Cymabay Therapeutics Inc (CBAY) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 Instagram:https://instagram. home loan programs for healthcare workersregulated offshore forex brokersnasdaq rxtselling options Find the latest CymaBay Therapeutics Inc. CBAY analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating. panw stoklucis stock Find real-time NOK - Nokia Oyj stock quotes, company profile, news and forecasts from CNN Business. mortgage companies in new york Based on analysts projections #CBAY is expected to experience a price decline over the next year. The current average CBAY price target, as estimated by these analysts, is $0.00.. The predictions for the future CBAY stock price range from a low of $0.00 to a high of $0.00, highlighting the variability of market expectations for CBAY.Traders may consider buying the stock or exploring call options. I backtested 91 similar cases where CBAY's Momentum Indicator exceeded 0, and 78 of them led t This indicator may be signaling that CBAY's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or ...